Hims & Hers Rockets 50% as Novo Nordisk Feud Turns Into Partnership

Sometimes the best business deals start with a lawsuit. Hims & Hers Health (NYSE: HIMS) is surging more than 50% in premarket trading Monday after Danish pharma giant Novo Nordisk agreed to sell its blockbuster weight-loss drugs — including Wegovy and Ozempic — directly through the Hims telehealth platform. The announcement ends a bitter legal feud that had hammered HIMS shares for weeks.

Here’s the backstory. Earlier this year, Hims launched a $49 compounded version of semaglutide — the active ingredient in Novo’s wildly popular GLP-1 drugs. Novo was not amused. They sued for patent infringement. The FDA piled on with its own crackdown threats. HIMS pulled the product and the stock cratered. Last year, Novo had already killed a short-lived Wegovy distribution deal with Hims over what it called aggressive marketing tactics. The relationship, in short, was toxic.

But here’s where it gets interesting. Instead of bleeding each other in court, the two companies flipped the script entirely. Under the new collaboration, Hims will offer branded FDA-approved GLP-1 medications through its platform while scaling back its compounded semaglutide offerings. For Novo, it’s a massive new distribution channel — Hims has millions of active telehealth users who are already searching for weight-loss treatments. For Hims, it’s instant legitimacy and the removal of a legal cloud that was crushing the stock.

The weight-loss drug market is projected to exceed $100 billion by the end of the decade, and the real battle isn’t just about who makes the drugs — it’s about who controls the patient relationship. Hims has built a sleek, direct-to-consumer telehealth machine that makes getting a prescription feel more like ordering from Amazon than visiting a doctor’s office. That’s exactly the kind of distribution power Novo needs as competition from Eli Lilly’s Zepbound intensifies.

Hims guided for $2.7 to $2.9 billion in revenue for 2026 — and that was before this deal was factored in. If branded GLP-1 prescriptions flow through the platform at scale, those numbers could look conservative. But investors should temper the euphoria with some caution: telehealth weight-loss regulation is tightening, Hims still needs to prove it can generate healthy margins on branded drugs (which carry much higher wholesale costs than compounded versions), and this partnership has fallen apart before.

Still, Wall Street loves a redemption arc. HIMS went from lawsuit target to strategic partner in less than 30 days. Whether this deal holds long-term will depend on execution, but for now, the market is voting with its wallet — and the verdict is decisively bullish.